W A P Breeman

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Radiolabelling DOTA-peptides with 68Ga
    Wouter A P Breeman
    Department of Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 32:478-85. 2005
  2. ncbi Radiolabelled regulatory peptides for imaging and therapy
    W A P Breeman
    Erasmus MC Rotterdam, University Medical Center Rotterdam, Department of Nuclear Medicine, Dr Molewaterplein 40, Rotterdam, The Netherlands
    Anticancer Agents Med Chem 7:345-57. 2007
  3. ncbi (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Semin Nucl Med 41:314-21. 2011
  4. ncbi The 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?
    Wouter A P Breeman
    Eur J Nucl Med Mol Imaging 34:978-81. 2007
  5. ncbi Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam s 3015 CE Rotterdam, The Netherlands
    Nucl Med Biol 35:839-49. 2008
  6. ncbi Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:917-20. 2003
  7. ncbi Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Nucl Med Biol 31:821-4. 2004
  8. ncbi Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate
    W H Bakker
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Q J Nucl Med Mol Imaging 50:265-71. 2006
  9. ncbi Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats
    E J Rolleman
    Department Nuclear Medicine, Room L244, Erasmus MC s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Nuklearmedizin 47:110-5. 2008
  10. ncbi Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer
    R P J Schroeder
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands, Department of Urology, Erasmus MCRotterdam, The Netherlands
    Q J Nucl Med Mol Imaging 56:468-75. 2012

Collaborators

Detail Information

Publications17

  1. ncbi Radiolabelling DOTA-peptides with 68Ga
    Wouter A P Breeman
    Department of Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 32:478-85. 2005
    ..Here we present the practical aspects and the results of radiolabelling DOTA-peptides with a TiO2-based commercially available 68Ge/68Ga generator...
  2. ncbi Radiolabelled regulatory peptides for imaging and therapy
    W A P Breeman
    Erasmus MC Rotterdam, University Medical Center Rotterdam, Department of Nuclear Medicine, Dr Molewaterplein 40, Rotterdam, The Netherlands
    Anticancer Agents Med Chem 7:345-57. 2007
    ..New analogues, chelators, radionuclides and combinations thereof are discussed...
  3. ncbi (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Semin Nucl Med 41:314-21. 2011
    ..As soon as these are achieved, a whole new radiopharmacy providing PET radiopharmaceuticals might develop...
  4. ncbi The 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?
    Wouter A P Breeman
    Eur J Nucl Med Mol Imaging 34:978-81. 2007
  5. ncbi Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam s 3015 CE Rotterdam, The Netherlands
    Nucl Med Biol 35:839-49. 2008
    ..In patient blood, the rank of radiopeptide in vivo stability was: (99m)Tc-Demogastrin 2 (t(1/2) 10-15 min)>(111)In-DOTA-CCK (t(1/2) approximately 5-10 min)>(111)In-DOTA-MG11 (t(1/2)<5 min)...
  6. ncbi Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:917-20. 2003
    ....
  7. ncbi Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Nucl Med Biol 31:821-4. 2004
    ..In conclusion, the addition of excess DTPA to [90Y-DOTA0,Tyr3]octreotide with incomplete 90Y-incorporation is recommended...
  8. ncbi Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate
    W H Bakker
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Q J Nucl Med Mol Imaging 50:265-71. 2006
    ....
  9. ncbi Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats
    E J Rolleman
    Department Nuclear Medicine, Room L244, Erasmus MC s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Nuklearmedizin 47:110-5. 2008
    ....
  10. ncbi Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer
    R P J Schroeder
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands, Department of Urology, Erasmus MCRotterdam, The Netherlands
    Q J Nucl Med Mol Imaging 56:468-75. 2012
    ..Besides frequently used androgen-resistant PC-3 also the clinically more relevant androgen sensitive VCaP celline was used as human PC xenograft in nude mice...
  11. ncbi Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts
    Rogier P J Schroeder
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 38:1257-66. 2011
    ..We compared GRPR-based targeting using the (68)Ga-labelled bombesin analogue AMBA with metabolism-based targeting using (18)F-methylcholine ((18)F-FCH) in nude mice bearing human prostate VCaP xenografts...
  12. ncbi Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors
    Paul J J M Janssen
    Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands
    Cancer Biother Radiopharm 22:374-81. 2007
    ..We concluded that DTPA-(Pip)Gly-Pro-(PipAm)Gly-Arg-Pro-Tyr-tBuGly-Leu-OH and the DOTA-linked counterpart have the most favorable biodistribution properties regarding tumor uptake...
  13. ncbi Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy
    Tomas Vitha
    Biocatalysis and Organic Chemistry, Department of Biotechnology, Delft University of Technology, Julianalaan 136, Delft, The Netherlands
    J Med Chem 51:677-83. 2008
    ..1 and 11 s(-1) mM(-1), respectively. An in vivo gamma-ray imaging study showed that the (177)Lu complexes of 2a and 2b have a high affinity for bones, particularly for growth plates and teeth with a prolonged retention...
  14. ncbi Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 104:376-9. 2003
    ..177)Lu-DOTA-tate showed anti-tumoral effects in both cases and significant survival in the PRRT-treated rats. (177)Lu-DOTA-tate is a very promising new treatment modality for SSR-positive tumors, including disseminated disease...
  15. ncbi The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus University Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:312-5. 2003
    ..After labelling [DOTA(0),Tyr(3)]octreotate with (177)Lu the addition of DTPA prior to intravenous administration of [(177)Lu-DOTA(0),Tyr(3)]octreotate is strongly recommended...
  16. ncbi The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy
    Gerrit D Slooter
    Department of Surgery, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 43:1681-7. 2002
    ..Radionuclide therapy could therefore be a promising treatment modality for patients with symptomatic liver metastases of neuroendocrine tumors in combination with liver resection...
  17. ncbi Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 43:1650-6. 2002
    ..Radiometal-labeled diethylenetriaminepentaacetic acid (DTPA)-BN derivatives are potentially useful radioligands for receptor-targeted scintigraphy and radiotherapy of GRP receptor-expressing tumors...